Trial · NCT04244006
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
NCT04244006, Phase 2, Phase 3, Terminated, University Hospital, Toulouse
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome. Trials, record NCT04244006. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04244006
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
- NCT number
- NCT04244006
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 10 participants, actual
- Lead sponsor
- University Hospital, Toulouse
- Conditions
- Netherton Syndrome
- Interventions
- Dupilumab Prefilled Syringe, Placebo Prefilled Syringe
- First posted
- 2020-01-28
- Last updated
- 2026-09-21
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The severity of the disease of the Netherton Area Severity Assessment score (NASA). | Day 0 and week 16 | NASA score |
| Secondary | Clinical efficacy severity of pruritus and pain | Day 0, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 28 | NASA score |
| Secondary | Presence of infections (adverse event) | Day 0, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 28 | Number of Bacterial or viral Skin infections |
| Secondary | Quantity of dermocorticosteroids used between each visit will be evaluated by questioning the patient. | Day 0, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 28 | number of tubes multiplied by the weight of one tube |
| Secondary | QOL score | Day 0, Week 16 and 28 | QOL score |
| Secondary | Skin inflammation | Day 0 and week 16 | number of inflammation markers on biopsies |
| Secondary | Protease activity | Day 0 and week 16 | number of protease markers on biopsies |
| Secondary | Microbiome qualitative and quantitative analysis | Day 0 and week 16 | number and form of bacteria |
| Secondary | Transepidermal water loss (TEWL) | Day 0 and Week 16 | Measured by a Tewameter applied on a standardized area in the anterior aspect of the forearm, |
| Secondary | Safety of dupilumab | Day 0, week 2, week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 28 | Blood tests performed every month until Week 16 (liver and renal tests, total blood count) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04244006
GET https://conductscience.org/api/trials/v1/NCT04244006/registered